Biosafety testing of a 293GP master cell bank used for production of patient-specifica gammaretroviral ventors encoding tcrs directed against tumor neoantigens.
Ended Awarded Last action
- Contract number
- HHSN26100019
- Awardee
-
Bioreliance Corporation UEI H3KAG9A26K77 Part of Sigma-Aldrich Corporation
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $127,773
Award facts
- Opportunity
-
- N02RC3600485 Solicitation number
- Biosafety Testing of GMP Master Cell Banks (MCB) and Retroviral Vectors for NCI Clinical Trials Award Notice · Posted Mar 7, 2013
- Contract value 100% obligated
- $127,772.70 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Rockville, MD 20850, USA
Award details come from SAM.gov/FPDS.
About this award
This is a delivery order contract awarded by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services, to Bioreliance Corporation, a foreign-owned, for-profit company providing specialized testing services. The $127,772.70 firm-fixed-price contract is for biosafety testing of a 293GP master cell bank used for production of patient-specific gammaretroviral vectors encoding TCRs directed against tumor neoantigens. The contract does not have a set-aside designation, indicating Bioreliance's competitive standing in the field of pharmaceutical and biotechnology safety testing. Bioreliance, through its Life Sciences Services Division, has a history of providing endotoxin, sterility, and general safety testing services to government agencies, including the National Institute of Allergy and Infectious Diseases (NIAID) and the Centers for Disease Control and Prevention (CDC). This contract award demonstrates Bioreliance's role in supporting the NCI's research and development initiatives related to cancer immunotherapy.
Quick answers
Who was awarded contract HHSN26100019?
HHSN26100019 was awarded to Bioreliance Corporation by National Cancer Institute (National Institutes of Health) on August 17, 2015.
How much is contract HHSN26100019 worth?
The government has obligated $127,773 on HHSN26100019.
Is contract HHSN26100019 an order under another contract?
Yes. HHSN26100019 is a delivery order under HHSN261201300026I, an indefinite delivery contract.
Was contract HHSN26100019 competed?
The extent of competition for HHSN26100019 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award